[Federal Register Volume 75, Number 134 (Wednesday, July 14, 2010)]
[Notices]
[Pages 40795-40796]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-17173]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[Docket 44-2010]
Review of Sourcing Change, Foreign-Trade Subzone 61H, Baxter
Healthcare of Puerto Rico (Inhalation Anesthetics Manufacturing),
Guayama, Puerto Rico
Pursuant to the regulations of the Foreign-Trade Zones (FTZ) Board
(the Board), a review has been initiated (under 15 CFR Sec.
400.28(a)(3)(iii)(A)) of changes in sourcing related to inhalation
anesthetics at Foreign-Trade Subzone 61H, at the facility of Baxter
Healthcare of Puerto Rico (Baxter).
Subzone 61H was approved by the FTZ Board on February 25, 1997
(Board Order 875, 62 FR 10521, 3/7/1997) at the Baxter Healthcare of
Puerto Rico (Baxter) (formerly Ohmeda Caribe Inc./Ohmeda Pharmaceutical
Manufacturing Inc.) facility in Guayama, Puerto Rico, for the
manufacturing and distribution of pharmaceutical products, primarily
inhalation anesthetics for hospital and critical care therapy. The
subzone was initially approved for a period of five years. On August
25, 2003 (Board Order 1293, 68 FR 53346, 9/10/2003), the subzone was
extended indefinitely and the scope of approved authority was expanded.
On products shipped to the U.S. market, the company is able to
choose the duty rate during customs entry procedures that applies to
the finished products (duty-free) for the otherwise dutiable foreign
components (duty rates range from duty-free to 20%).
Baxter has now notified the Board of additional sourcing of two
chemical inputs. The new foreign-sourced chemical ingredients are
sevomethylether (HTSUS 2909.19.1800 5.5%) and N,N-diisopropylethylamine
(HTSUS 2921.19.6090 - 6.5%). The use of zone procedures for the
additional inputs could exempt Baxter from customs duty payments on the
foreign components used in export production. The company estimates
that some 40 percent of the plant's shipments are exported. On the
domestic sales, Baxter would be able to choose the duty rate during
customs entry procedures that applies to the finished inhalation
anesthetics (duty-free) for the foreign inputs noted above. The
finished products remain unchanged and were included in the scope of
manufacturing authority approved by the Board.
In accordance with the Board's regulations, Diane Finver of the FTZ
Staff is designated examiner to investigate the sourcing change,
including its potential to cause ``significant adverse effects'' (15
CFR 400.28(a)(3)(iii)(A)), and report to the Board. Public comment is
invited from interested parties. Submissions (original and 3 copies)
shall be addressed to the Board's Executive Secretary at the address
below. The closing period for their receipt is August 13, 2010.
Rebuttal comments in response to material submitted during the
foregoing period may be submitted during the subsequent 15-day period
to August 30, 2010.
A copy of the application will be available for public inspection
at the Office of the Executive Secretary, Foreign-Trade Zones Board,
Room 2111, U.S. Department of Commerce, 1401 Constitution Avenue, NW,
Washington, DC 20230-0002, and in the
[[Page 40796]]
``Reading Room'' section of the Board's website, which is accessible
via www.trade.gov/ftz.
For further information, contact Diane Finver at
[email protected] or 482-1367.
Dated: July 2, 2010.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2010-17173 Filed 7-13-10; 8:45 am]
BILLING CODE 3510-DS-S